Strengthening your care for patients
Industry experts share the latest interventional techniques and provide their advice on how best to adopt them within clinical practice.
About our programsIndustry experts share the latest interventional techniques and provide their advice on how best to adopt them within clinical practice.
About our programsEdwards Benchmark Program
Our program may support your heart centre in optimising its transcatheter aortic valve implantation (TAVI) care pathway for better patient outcomes.
Learn moreTips and Techniques
Explore case recordings, expert-delivered educational videos on procedural challenges, tips and techniques, peer interviews and more.
View videosLearning Portal
Edwards Learning Network, an educational portal for healthcare professionals providing continuous learning and development in structural heart intervention.
Find out moreHear from key industry physicians about their TAVI experiences.
Learn moreThe latest transcathether heart valve in the
The first TAVI valve to receive a CE mark for severe aortic stenosis (sAS) patients at low surgical risk.
Edwards valve proving non-inferior to surgery on mortality and stroke in the PARTNER IIA Trial.1
Introduced as a lifesaving treatment option for inoperable and high surgical risk patients.2,3
Overview of studies conducted with balloon expandable TAVI valves by Edwards Lifesciences.
Read PARTNER dataLearn how the Edwards clinical trial programme has shaped the aortic stenosis treatment landscape.
Uncover the wide-ranging economic and quality of life benefits possible with the Edwards SAPIEN 3 transcatheter heart valve.4
Useful for you and your patients, including heart anatomy guide, clinical summary PDFs and more.
Access resourcesThank you for signing up to the heartvalves.com newsletter. You will now receive emails on the latest developments and industry insights on heart valve innovation and technology.
References:
1. Leon MB, et al. N Engl J Med 2016;374:1609-1620 and supplementary material.
2. Leon MB, Smith CR, Mack M, et al; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-607.
3. Smith CR, Leon MB, Mack MJ, et al.; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364:2187-98.
4. Cohen DJ. Economic Outcomes of TAVR vs SAVR for Low-Risk Patients: Results from PARTNER 3 Trial. Presented at TCT 2021, Orlando Fl. November 5th 2021.
For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
PP--EU-3351 v1.0